Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090687 | 0.79 | DPYD (0.50) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL102177 | 0.76 | ATAD2 (0.52) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL1506328 | 0.72 | DPYD (0.44) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL1061623 | 0.72 | GAA (0.48) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL5075425 | 0.71 | SLC22A6 (0.47) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL1916526 | 0.71 | ATAD2 (0.47) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL6647291 | 0.71 | POLB (0.50) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL17991917 | 0.69 | GAA (0.45) | DPYDALDH1A1MAPTLMNAGAA | |
| SCHEMBL1748619 | 0.68 | ALDH1A1 (0.50) | DPYDALDH1A1MAPTLMNAGAA | |
| Formaldehyde SCHEMBL28861115 | 0.68 | POLB (0.48) | DPYDALDH1A1MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2590960-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2603501-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| EP-2590960-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-8283360-B2 | Bicyclic heterocyclic derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012020037-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012004212-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | SCHERING PLOUGH CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-8063072-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2379564-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LI JIM | 2011-03-24 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
| WO-2010071819-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1861095-A1 | DERIVATIVES OF IMIDAZO(1,2-A)PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100119-A1 | DERIVATIVES OF IMIDAZO (1,2-A) PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | DPYD 259/4885ALDH1A1 597/4885MAPT 4592/4885 |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | DPYD 386/4885ALDH1A1 1266/4885MAPT 4670/4885 |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | ALPI, PYGL, PPIP5K2 | DPYD 21/4885ALDH1A1 627/4885MAPT 4010/4885 |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | GPR119, GID4, TLR4 | DPYD 1035/4885ALDH1A1 1161/4885MAPT 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.